Verastem (VSTM) Cash from Financing Activities (2011 - 2026)
Verastem (VSTM) recorded quarterly Cash from Financing Activities of $28.7 million in Q1 2026, down 70.9% quarter-over-quarter from $98.6 million in Q4 2025, and down 57.45% on a YoY basis from $67.4 million in Q1 2025.
Verastem (VSTM) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Verastem's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $28.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 57.45% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $224.6 million (up 85.04% YoY), while the FY2025 annual figure was $263.3 million, up 380.64% from the prior year.
- Cash from Financing Activities was $28.7 million for Q1 2026 at Verastem, down from $98.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $98.6 million in Q4 2025 to a low of -$891000.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged $33.3 million across 5 years, with a median of $25.5 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 103.48% in 2023, then surged 19708.89% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $25.6 million in 2022, then plunged by 101.74% to -$446000.0 in 2023, then surged by 266.37% to $742000.0 in 2024, then soared by 13186.12% to $98.6 million in 2025, then slumped by 70.9% to $28.7 million in 2026.
- The last three Cash from Financing Activities figures came in at $28.7 million (Q1 2026), $98.6 million (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | 28.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.69 Mn |
| Mar 31, 2026 | 28.69 Mn |
| Dec 31, 2025 | 98.58 Mn |
| Dec 31, 2025 | 98.58 Mn |
| Sep 30, 2025 | 17.88 Mn |
| Sep 30, 2025 | 17.88 Mn |
| Jun 30, 2025 | 79.42 Mn |
| Jun 30, 2025 | 79.42 Mn |
| Mar 31, 2025 | 67.43 Mn |
| Mar 31, 2025 | 67.43 Mn |
| Dec 31, 2024 | 742,000.00 |
| Dec 31, 2024 | 742,000.00 |
| Sep 30, 2024 | 53.60 Mn |
| Sep 30, 2024 | 53.60 Mn |
| Jun 30, 2024 | -405,000.00 |
| Jun 30, 2024 | -405,000.00 |
| Mar 31, 2024 | 846,000.00 |
| Mar 31, 2024 | 846,000.00 |
| Dec 31, 2023 | -446,000.00 |
| Dec 31, 2023 | -446,000.00 |